Clinical development is converging on four forces: participant‑centricity, technology, real-world evidence (RWE), and inspection readiness. Sponsors are designing trials to meet patients where they are, leveraging technology and RWE. These trials must be designed to ensure accountability, data integrity, and inspection readiness, because the public can now see trial deficiencies through the U.S. Food and Drug Administration (FDA)'s public release of complete response letters (CRLs).

Participant‑centric operations, done rigorously. FDA's guidance on "Conducting Clinical Trials With Decentralized Elements" embraces decentralized trial elements: telehealth, home health, local labs, direct‑to‑patient supply, and remote assessments. FDA expects defined party roles, traceable data flows, and well-documented safety oversight. Protocols and investigational plans should prespecify what occurs remotely vs. on‑site, how investigators supervise third parties, how investigational products are controlled off‑site, and how data origin is recorded from capture through analysis. If electronic clinical outcome assessments (eCOAs) or other electronic systems are the source of record, Part 11 controls (validation, access, audit trails) apply.

Digital Health Technologies (DHTs). Sensors, wearables, and apps are increasingly being used by sponsors to lower patient burden and increase real time data capture. Even where these DHTs have wellness‑only features that fall outside device requirements or are subject to enforcement discretion, standards for validation do not change. DHTs used in clinical trials must be fit‑for‑purpose for the target population and context, with verified and validated measurement performance, defined user training, and version/algorithm control. Read the full Digital Health chapter here.

Bayesian approaches. FDA's January 2026 Guidance, Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products confirms its receptiveness to adaptive, Bayesian, and external‑control approaches – especially for rare diseases – provided adaptations are prospectively defined, priors/borrowing are justified, and operating characteristics are transparent.

Inspections. Real‑time publication of complete response letters (CRLs) for products that are not yet approved makes clinical deficiencies visible to the public more immediately. BIMO findings most often involve (1) designs not "adequate and well‑controlled" (misaligned endpoints, weak or absent controls, underspecified analyses); (2) data‑integrity and electronic‑records lapses (incomplete or delayed source data, insufficient audit trails, ineffective CAPA); and (3) insufficient sponsor oversight. Given FDA's expanded unannounced inspections abroad, sponsors and foreign sites should maintain safeguards that prevent these issues.

Looking forward: As FDA embraces participant‑centric, tech‑enabled trials that combine decision‑grade RWE with adaptive designs, sponsors must continue to maintain accountability, data integrity, and inspection readiness as real‑time transparency and expanded foreign scrutiny intensify.